Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G W Sledge

Showing results (61-70 of 112) with videos related to

Pageof 12
Sort By:
Experimental Hematology|June 1, 1986
Monoclonal antibody (II2C) to human lactoferrin inactivates the myelopoietic suppressive effect of human lactoferrin in vitroG W Sledge, D C Bicknell, E L Harris, et al.
Investigational New Drugs|May 1, 1993
5-Azacytidine (NSC 102816) in refractory germ cell tumors. A phase II trial of the Eastern Cooperative Oncology GroupB J Roth, P Elson, G W Sledge, et al.
Cancer|May 17, 2000
Effects of high dose raloxifene in selected patients with advanced breast carcinomaW Gradishar, J Glusman, Y Lu, et al.
Life Sciences|January 1, 1994
Coordinated increase in activities of the signal transduction enzymes PI kinase and PIP kinase in human cancer cellsR L Singhal, Y A Yeh, K Y Look, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2011
A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology GroupK D Miller, A O'Neill, E A Perez, et al.
Journal of Steroid Biochemistry|January 1, 1986
An estrogen-regulated protein in normal and malignant endometriumW L McGuire, L G Dressler, G W Sledge, et al.
International Journal of Andrology|February 1, 1987
Flow cytometry derived DNA content of the primary lesions of advanced germ cell tumoursG W Sledge, J N Eble, B J Roth, et al.
Biochemical and Biophysical Research Communications|March 8, 1995
Quercetin down-regulates signal transduction in human breast carcinoma cellsR L Singhal, Y A Yeh, N Praja, et al.
American Journal of Clinical Oncology|June 1, 1984
Phase II trial of vindesine in patients with squamous cell cancer of the head and neckG W Sledge, G M Clark, C Griffin, et al.
European Journal of Cancer (Oxford, England : 1990)|April 28, 2004
MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trialsM Extermann, M Bonetti, G W Sledge, et al.
Pageof 12

Showing results (61-70 of 112) with videos related to

Sort By:
Pageof 12
Experimental Hematology|June 1, 1986
Monoclonal antibody (II2C) to human lactoferrin inactivates the myelopoietic suppressive effect of human lactoferrin in vitroG W Sledge, D C Bicknell, E L Harris, et al.
Investigational New Drugs|May 1, 1993
5-Azacytidine (NSC 102816) in refractory germ cell tumors. A phase II trial of the Eastern Cooperative Oncology GroupB J Roth, P Elson, G W Sledge, et al.
Cancer|May 17, 2000
Effects of high dose raloxifene in selected patients with advanced breast carcinomaW Gradishar, J Glusman, Y Lu, et al.
Life Sciences|January 1, 1994
Coordinated increase in activities of the signal transduction enzymes PI kinase and PIP kinase in human cancer cellsR L Singhal, Y A Yeh, K Y Look, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2011
A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology GroupK D Miller, A O'Neill, E A Perez, et al.
Journal of Steroid Biochemistry|January 1, 1986
An estrogen-regulated protein in normal and malignant endometriumW L McGuire, L G Dressler, G W Sledge, et al.
International Journal of Andrology|February 1, 1987
Flow cytometry derived DNA content of the primary lesions of advanced germ cell tumoursG W Sledge, J N Eble, B J Roth, et al.
Biochemical and Biophysical Research Communications|March 8, 1995
Quercetin down-regulates signal transduction in human breast carcinoma cellsR L Singhal, Y A Yeh, N Praja, et al.
American Journal of Clinical Oncology|June 1, 1984
Phase II trial of vindesine in patients with squamous cell cancer of the head and neckG W Sledge, G M Clark, C Griffin, et al.
European Journal of Cancer (Oxford, England : 1990)|April 28, 2004
MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trialsM Extermann, M Bonetti, G W Sledge, et al.
Pageof 12